KH176

DRUG3 trials

Sponsors

Khondrion BV

Conditions

LHONLeigh SyndromeMELASMELAS SyndromeMIDDMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationMitochondrial DiseaseMitochondrial Diseases

Phase 1

A Dose-escalating Clinical Trial With KH176

CompletedNCT02544217

Khondrion BVLeigh Syndrome, LHON, MELAS +2

Start: 2015-05-31End: 2015-10-31Updated: 2021-10-18

Phase 2

The KHENERGY Study

CompletedNCT02909400

Khondrion BVMELAS, MIDD, Mitochondrial Diseases +2

Start: 2016-09-30End: 2017-07-31Updated: 2018-02-23

The KHENERGYZE Study

CompletedNCT04165239

Khondrion BVMELAS Syndrome, MIDD, Mitochondrial Diseases +2

Start: 2019-10-30End: 2022-05-24Updated: 2022-08-31

Related Papers

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC").

2022-04-279 citations

The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.

2018-09-0344 citations

KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers.

2017-10-1629 citations